2X-121 Market Size, Forecast, and Emerging Insight - 2032

“2X-121 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about 2X-121 for ovarian cancer in the six major markets. A detailed picture of the 2X-121 for ovarian cancer in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the 2X-121 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the 2X-121 market forecast analysis for ovarian cancer in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary

2X-121 (Stenoparib) is a unique, small molecule dual-targeted inhibitor of PARP 1 and 2 and telomerase maintenance enzymes (Tankyrase 1 and 2). It is an orally bioavailable, small-molecule inhibitor of enzymatic activity and helps trap PARP1 on DNA via dose-dependent binding to chromatin. In addition, it inhibits tankyrase 1 and 2, which are important regulators of the canonical Wnt/β-catenin signaling pathway involved in promoting tumorigenesis. Stenoparib has also demonstrated single-agent antitumor activity in several BRCA-deficient xenograft models and potentiated the efficacy of radiotherapy and chemotherapy in both in vitro and in vivo models.

Currently, the molecule is under investigation ass a single-agent therapy in a Phase II clinical trial for patients with advanced ovarian cancer who have had ≥2 or more previous chemotherapies, including potential treatment with other PARP inhibitors.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the 2X-121 description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on 2X-121 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the 2X-121 research and development activities in ovarian cancer across the United State and Europe.
• The report also covers the patents information with expiry timeline around 2X-121.
• The report contains forecasted sales of 2X-121 for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for 2X-121 in ovarian cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

2X-121 Analytical Perspective

In-depth 2X-121 Market Assessment

This report provides a detailed market assessment of 2X-121 for ovarian cancer in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2027 to 2032.

2X-121 Clinical Assessment

The report provides the clinical trials information of 2X-121 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence 2X-121 dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to 2X-121 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of 2X-121 in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of 2X-121 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the 2X-121 in ovarian cancer.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of 2X-121?
• What is the clinical trial status of the study related to 2X-121 in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the 2X-121 development?
• What are the key designations that have been granted to 2X-121 for ovarian cancer?
• What is the forecasted market scenario of 2X-121 for ovarian cancer?
• What are the forecasted sales of 2X-121 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom?
• What are the other emerging products available and how are these giving competition to 2X-121 for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

This product will be delivered within 2 business days.